HCW Biologics, Inc. HCWB 深 滬
已收盤 04-02 16:00:00 美东时间
0.2679
-0.032
-10.70%
華盛通- 最 高0.2927
- 今 開0.259
- 成交量 77.55万股
- 最 低 0.25
- 昨 收 0.30
- 總市值 94.22万
- 52周最高 17.7999
- 市盈率 靜 --
- 換手率 22.05%
- 52周最低 0.25
- 委 比 18.76%
- 總股本 351.68万
- 歷史最高 311.00
- 量 比 1.18
- 振 幅 14.23%
- 歷史最低 0.25
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
HCW Biologics shares are trading lower after the company reported a year-over-year decrease in Q4 sales results.
HCW Biologics shares are trading lower after the company reported a year-over-y...
04-01 23:38
HCW Biologics Q4 EPS $(1.02) Up From $(3.19) YoY, Sales $27.010K Down From $394.804K YoY
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(1.02) per share. This is a 68.03 percent increase over losses of $(3.19) per share from the same period last year. The company reported $27.010 thousand in
04-01 05:19
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Fr...
03-21 05:05
HCW Biologics shares are trading higher after the company announced results for HCW9206 production platform for CAR-T cell therapies.
HCW Biologics shares are trading higher after the company announced results for...
03-16 21:27
HCW Biologics Regains Nasdaq Compliance
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link
03-02 21:14
HCW Biologics, WY Biotech Commence License Agreement To Deploy, Commercialize Rights For Certain In Vivo Applications For HCW11-006
HCW Biologics Inc. ("HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link
02-13 21:36
HCW Biologics Begins Phase 1 Trial for HCW9302
The latest update is out from HCW Biologics ( ($HCWB) ). On November 18, 2025, ...
2025-11-18 20:59
HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $1.58 by 227.85 percent. This is a 49.5 percent increase over losses of $(4.00) per share from the
2025-11-15 05:47
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported its third-quarter 2025 financial results and business highlights, including the planned Phase 1 clinical trial for HCW9302, a novel immunotherapy targeting autoimmune diseases, and the launch of a search for a commercial partner for its T-cell engager compounds. The company also highlighted the IND-enabling studies for HCW9302 and showcased data for its second-generation TCE and immune checkpoint inhibitor programs. Despite...
2025-11-14 21:44
